Medpage Today on MSN2d
First Drug OK'd for Chronic Rhinosinusitis With Nasal Polyps in Adolescents
The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...
GlobalData on MSN3d
Regeneron’s Dupixent approved as first adolescent CRSwNP treatment
The safety profile of Dupixent in adolescents with moderate-to-severe asthma contributed to the FDA's decision.
Zacks.com on MSN3d
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.
Morningstar6d
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has ...
Monthly Prescribing Reference6d
Dupixent Approval Expanded to Include Adolescent Patients With CRSwNP
The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® (dupilumab) to include add-on maintenance treatment of adolescent patients aged 12 to 17 years with inadequately ...
Verywell Health on MSN12mon
Sinus Infection vs. Cold: How to Tell the Difference
Jassey, DOSinus infection symptoms and cold symptoms often appear similar, but there are some key differences that impact ...
FierceBiotech1d
Inflammation-focused Upstream set to join growing trickle of biotech IPOs
The fall flurry of biotech IPOs shows no signs of abating, with Upstream Bio becoming the latest company to express an ...